IP Library Granted Patent US 11,541,080
Granted Patent B2
US 11,541,080 · App. 17/735,743 · Granted Jan 3, 2023

Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them

Inventor: Thomas J. Borody (Five Dock, AU)
Assignee: Finch Therapeutics Holdings LLC
A61K35/74A61K9/4891A61K35/24A61K35/742A61M39/00A61P1/12C12N1/00C12N1/20A61B10/0038A61K9/4875A61K2035/115A61M5/142A61M31/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,541,080
App. No.
17/735,743
Granted
Jan 3, 2023
Kind
B2
Abstract

In alternative embodiments, the invention provides enema delivery systems or enema products comprising compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.

Claims (29)

1. An enema delivery system configured for transporting to a remote facility,

the enema delivery system comprising a sealed container, a tubing equipment, and a pharmaceutical composition within the sealed container,

wherein the pharmaceutical composition is formulated for enema delivery from the sealed container via the tubing equipment,

wherein the pharmaceutical composition comprises a microbiota suspension comprising a cryoprotectant and viable uncultured non-pathogenic fecal bacteria from a stool of a human donor that has been prescreened for infectious agents, and

wherein the pharmaceutical composition is stable during long term storage of the sealed container when frozen.

2. The enema delivery system of claim 1 , wherein the system protects the fecal bacteria within the pharmaceutical composition from destruction when the sealed container is frozen or exposed to air.

3. The enema delivery system of claim 1 , wherein the sealed container comprises a gas impervious or oxygen-resistant material.

4. The enema delivery system of claim 1 , wherein the viable uncultured non-pathogenic fecal bacteria comprise anaerobic bacteria.

5. The enema delivery system of claim 1 , wherein the stool of a human donor is received at a central location.

6. The enema delivery system of claim 1 , wherein the tubing equipment can be attached to a colonoscope for enema delivery.

7. The enema delivery system of claim 1 , wherein the tubing equipment is attached to a pump with a one-way valve.

8. The enema delivery system of claim 1 , wherein the cryoprotectant is glycerol.

9. The enema delivery system of claim 1 , wherein the pharmaceutical composition further comprises anti-oxidants.

10. The enema delivery system of claim 1 , wherein the pharmaceutical composition is homogenized.

11. The enema delivery system of claim 3 , wherein the oxygen-resistant material is aluminum-metallized polyethylene terephthalate polyester film.

12. An enema product configured for transporting to a remote facility, the enema product comprising a sealed container, a tubing equipment, and a pharmaceutical composition within the sealed container,

wherein the pharmaceutical composition is formulated for enema delivery from the sealed container via the tubing equipment,

wherein the pharmaceutical composition comprises a microbiota suspension comprising a cryoprotectant and viable uncultured non-pathogenic fecal bacteria from a stool of a human donor that has been prescreened for infectious agents,

wherein the pharmaceutical composition is stable during long term storage of the sealed container when frozen, and

wherein the pharmaceutical composition is in an amount effective for treating recurrence of C. difficile infection, acute pseudo membranous colitis, severe C. difficile infection, septicemia or other comparable conditions.

13. The enema product of claim 12 , wherein the product protects the fecal bacteria within the pharmaceutical composition from destruction when the sealed container is frozen or exposed to air.

14. The enema product of claim 12 , wherein the sealed container comprises a gas impervious or oxygen-resistant material.

15. The enema product of claim 12 , wherein the fecal bacteria comprise anaerobic bacteria.

16. The enema product of claim 12 , wherein the tubing equipment can be attached to a colonoscope for enema delivery.

17. The enema product of claim 12 , wherein the tubing equipment is attached to a pump with a one-way valve.

18. The enema product of claim 12 , wherein the cryoprotectant is glycerol.

19. The enema product of claim 12 , wherein the pharmaceutical composition further comprises anti-oxidants.

20. The enema product of claim 12 , wherein the pharmaceutical composition is homogenized.

21. The enema product of claim 14 , wherein the oxygen-resistant material is aluminum-metallized polyethylene terephthalate polyester film.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2022
From: BORODY, THOMAS J.
To: CRESTOVO HOLDINGS, LLC
Reel/Frame 059901/0377 →
CHANGE OF NAME Recorded May 13, 2022
From: CRESTOVO HOLDINGS, LLC
To: FINCH THERAPEUTICS HOLDINGS LLC
Reel/Frame 060065/0557 →
Priority Claims (1)
AU 2010903474 · Aug 4, 2010 · national
Continuity (15)
Continuation 17496398 · Oct 7, 2021
Continuation 16523726 · Jul 26, 2019
Continuation 16433437 · Jun 6, 2019
Continuation 16364144 · Mar 25, 2019
Continuation 16118400 · Aug 30, 2018
Continuation 15975456 · May 9, 2018
Continuation 15950939 · Apr 11, 2018
Continuation 15782519 · Oct 12, 2017
Continuation 15093679 · Apr 7, 2016
Continuation 13813915
Provisional Application 61494363 · Jun 7, 2011
Provisional Application 61483487 · May 6, 2011
Provisional Application 61451087 · Mar 9, 2011
Provisional Application 61450099 · Mar 7, 2011
Related Publication 20220257672A1 · Aug 18, 2022